FoxM1在膀胱尿路上皮癌中的研究进展

倪 璐, 宋旭 东*
华北理工大学附属医院病理科 河北唐山 063000

摘要

摘要:膀胱尿路上皮癌约占膀胱癌的90%，多数表现为典型的乳头状，是发病率和死亡率最高的肿瘤之一，也是第二常见的泌尿外科癌症。FoxM1定位于染色体带的12p13-3，长度大约为25kb，其编码基因主要是由10个外显子组成。FoxM1是一种关键的细胞周期调节因子。它控制G1/S和G2/M转换所需基因的表达；它对有丝分裂的进入和进展至关重要，确保维持染色体的稳定性。FoxM1在癌症的进展、侵袭和转移中起着重要作用，有可能被是早期诊断的潜在候选生物标志物和癌症治疗的靶点。在临床实践中，检测FoxM1蛋白表达和基因扩增可以帮助临床医生制定更有效的化疗方案，有助于判断疾病进展以及预测患者预后。本文总结FoxM1在膀胱尿路上皮癌中的表达及临床意义，以期为临床膀胱尿路上皮癌的治疗提供新的理论依据和治疗靶标。

关键词

关键词：FoxM1；膀胱尿路上皮癌；文献综述

参考

[1] Wang G, Mckenney J K. Urinary Bladder Pathology: World

Health Organization Classification and American Joint Committee on

Cancer Staging Update[J]. Arch Pathol Lab Med, 2019, 143(5):

571-577.

[2] Green D A, Rink M, Xylinas E, et al. Urothelial carcinoma of

the bladder and the upper tract: disparate twins[J]. J Urol, 2013,

189(4): 1214-21.

[3] 何旺, 黄海. 2022 ASCO-GU 尿路上皮癌精粹解析[J].

中华泌尿外科杂志, 2022, 43(04): 245-248.

[4] Lu M, Hu K. Correlation of HER2 and FOXM1 in human

colorectal carcinoma and its clinical significance[J]. International

journal of clinical and experimental pathology, 2017, 10(12):

11624-11634.

[5] Myatt S S, Lam E W. The emerging roles of forkhead box

(Fox) proteins in cancer[J]. Nat Rev Cancer, 2007, 7(11): 847-59.

[6] Hegde N S, Sanders D A, Rodriguez R, et al. The

transcription factor FOXM1 is a cellular target of the natural product

thiostrepton[J]. Nat Chem, 2011, 3(9): 725-31.

[7] Ye H, Kelly T F, Samadani U, et al. Hepatocyte nuclear

factor 3/fork head homolog 11 is expressed in proliferating epithelial

and mesenchymal cells of embryonic and adult tissues[J]. Molecular

and Cellular Biology, 1997, 17(3): 1626-1641.

[8] Borhani S, Gartel A L. FOXM1: a potential therapeutic target

in human solid cancers[J]. Expert Opin Ther Targets, 2020, 24(3):

205-217.

[9] Nakamura S, Hirano I, Okinaka K, et al. The FOXM1

transcriptional factor promotes the proliferation of leukemia cells

through modulation of cell cycle progression in acute myeloid

leukemia[J]. Carcinogenesis, 2010, 31(11): 2012-21.

[10] Liu D, Zhang Z, Kong C Z. High FOXM1 expression was

associated with bladder carcinogenesis[J]. Tumour Biol, 2013, 34(2):

1131-8.

[11] Fu M, Chen H, Cai Z, et al. Forkhead box family

transcription factors as versatile regulators for cellular

reprogramming to pluripotency[J]. Cell Regen, 2021, 10(1): 17.

[12] Koo C Y, Muir K W, Lam E W. FOXM1: From cancer

initiation to progression and treatment[J]. Biochim Biophys Acta,

2012, 1819(1): 28-37.

[13] Chen Y, Wang B C, Xiao Y. PI3K: A potential therapeutic

target for cancer[J]. Journal of Cellular Physiology, 2012, 227(7):

2818-2821.

[14] Wang Z, Banerjee S, Kong D, et al. Down-regulation of

Forkhead Box M1 transcription factor leads to the inhibition of

invasion and angiogenesis of pancreatic cancer cells[J]. Cancer Res,

2007, 67(17): 8293-300.

[15] Yoshida Y, Wang I C, Yoder H M, et al. The forkhead box

M1 transcription factor contributes to the development and growth of

mouse colorectal cancer[J]. Gastroenterology, 2007, 132(4):1420-31.

[16] Balli D, Zhang Y, Snyder J, et al. Endothelial

Cell–Specific Deletion of Transcription Factor FoxM1 Increases

Urethane-Induced Lung Carcinogenesis[J]. Cancer Research, 2011,

71(1): 40-50.

[17] Kalin, T. V. Increased Levels of the FoxM1 Transcription

Factor Accelerate Development and Progression of Prostate

Carcinomas in both TRAMP and LADY Transgenic Mice[J]. Cancer

Research, 2006, 66(3): 1712.

[18] Wang I C, Meliton L, Tretiakova M, et al. Transgenic

expression of the forkhead box M1 transcription factor induces

formation of lung tumors[J]. Oncogene, 2008, 27(30): 4137-49.

[19] Nilsson J, Helou K, Kovacs A, et al. Nuclear

Janus-activated kinase 2/nuclear factor 1-C2 suppresses

tumorigenesis and epithelial-to-mesenchymal transition by

repressing Forkhead box F1[J]. Cancer Res, 2010, 70(5): 2020-9.

[20] Frau M, Biasi F, Feo F, et al. Prognostic markers and

putative therapeutic targets for hepatocellular carcinoma[J]. Mol

Aspects Med, 2010, 31(2): 179-93.

[21] Chu X Y, Zhu Z M, Chen L B, et al. FOXM1 expression

correlates with tumor invasion and a poor prognosis of colorectal

cancer[J]. Acta Histochem, 2012, 114(8): 755-62.

[22] Seyedabadi S, Saidijam M, Najafi R, et al. Assessment of

CEP55, PLK1 and FOXM1 expression in patients with bladder

cancer in comparison with healthy individuals[J]. Cancer Invest,

2018, 36(8): 407-414.

[23] Uddin S, Ahmed M, Hussain A, et al. Genome-wide

expression analysis of Middle Eastern colorectal cancer reveals

FOXM1 as a novel target for cancer therapy[J]. American Journal of

Pathology, 2011, 178(2): 537-547.

[24] Priller M, Poschl J, Abrao L, et al. Expression of FoxM1 is

required for the proliferation of medulloblastoma cells and indicates

worse survival of patients[J]. Clinical Cancer Research An Official

Journal of the American Association for Cancer Research, 2011,

17(21): 6791-801.

[25] Yun-Yong P, Yun J S, Jennings N B, et al. FOXM1

mediates Dox resistance in breast cancer by enhancing DNA repair[J].

Carcinogenesis, 2012, 33(10): 10.

[26] Ueno H, Nakajo N, Watanabe M, et al. FoxM1-driven cell

division is required for neuronal differentiation in early Xenopus

embryos[J]. Development, 2008, 135(11): 2023-30.

[27] Kuda M, Kohashi K, Yamada Y, et al. FOXM1 expression

in rhabdomyosarcoma: a novel prognostic factor and therapeutic

target[J]. Tumor Biology, 2016, 37(4): 5213-5223.

[28] Wen N, Wang Y, Wen L, et al. Overexpression of FOXM1

predicts poor prognosis and promotes cancer cell proliferation,

migration and invasion in epithelial ovarian cancer[J]. Journal of

Translational Medicine, 2014, 12(1): 134-147.

[29] Yi L, Wang H, Li W, et al. The FOXM1/RNF26/p57 axis

regulates the cell cycle to promote the aggressiveness of bladder

cancer[J]. Cell Death Dis, 2021, 12(10): 944-956.

[30] Rinaldetti S, Wirtz R M, Worst T S, et al. FOXM1 predicts

overall and disease specific survival in muscle-invasive urothelial

carcinoma and presents a differential expression between bladder

cancer subtypes[J]. Oncotarget, 2017, 8(29): 47595-47606.

[31] 曹煜东, 杜鹏. 肌层浸润性膀胱癌分子分型的研究进

展[J]. 中华泌尿外科杂志, 2019, 40(6): 477-480.

[32] Wulfing C, Machiels J P, Richel D J, et al. A single-arm,

multicenter, open-label phase 2 study of lapatinib as the second-line

treatment of patients with locally advanced or metastatic transitional

cell carcinoma[J]. Cancer, 2009, 115(13): 2881-90.

[33] Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in

metastatic urothelial carcinoma after platinum therapy (CheckMate

275): a multicentre, single-arm, phase 2 trial[J]. Lancet Oncol, 2017,

18(3): 312-322.

[34] Babjuk M, Oosterlinck W, Sylvester R, et al. EAU

guidelines on non-muscle-invasive urothelial carcinoma of the

bladder[J]. Eur Urol, 2008, 54(2): 303-14.

[35] Sharma P, Callahan M K, Bono P, et al. Nivolumab

monotherapy in recurrent metastatic urothelial carcinoma

(CheckMate 032): a multicentre, open-label, two-stage, multi-arm,

phase 1/2 trial[J]. Lancet Oncol, 2016, 17(11): 1590-1598.

[36] Choi W, Porten S, Kim S, et al. Identification of distinct

basal and luminal subtypes of muscle-invasive bladder cancer with

different sensitivities to frontline chemotherapy[J]. Cancer Cell, 2014,

25(2): 152-165.

[37] Hedegaard J, Lamy P, Nordentoft I, et al. Comprehensive

Transcriptional Analysis of Early-Stage Urothelial Carcinoma[J].

Cancer Cell, 2016, 30(1): 27-42.